Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?

Area of Science:

• Oncology
• Genetics
• Genomics

Background:

• Soft-tissue sarcomas are diverse cancers affecting both adults and children.
• Next-generation sequencing (NGS) has revealed genetic complexity in sarcomas, suggesting potential therapeutic targets.
• Previous studies indicate actionable mutations in up to 50% of sarcoma patients, with retrospective data suggesting clinical benefit from targeted therapies.

Purpose of the Study:

• To investigate the role of targeted next-generation sequencing (NGS) in identifying actionable mutations in soft-tissue sarcoma patients.
• To evaluate the potential of implementing NGS to improve outcomes for metastatic sarcoma patients through genomically guided treatments.

Main Methods:

• Review of large studies investigating targeted NGS for actionable mutations in soft-tissue sarcomas.
• Reference to the MULTISARC randomized phase 3 trial assessing NGS implementation in metastatic sarcoma patients.

Main Results:

• Actionable genomic alterations were identified in up to 50% of patients in prior studies.
• Retrospective data suggest that genomically guided treatments may offer clinical benefits for advanced sarcoma.

Conclusions:

• A significant proportion of soft-tissue sarcomas harbor targetable genomic alterations detectable by NGS.
• Prospective data are needed to support routine NGS implementation in sarcoma management.
• The MULTISARC trial aims to provide evidence on whether NGS improves outcomes in metastatic sarcoma by enabling additional genomically guided treatment options.